CD274 and colorectal carcinoma: At the ASCO-GI 2019 meetings, the CCTG CO.26 trial (NCT02870920) compared the efficacy of the combinational regimen including a PD-L1 inhibitor durvalumab plus a CTLA-4 blockade tremelimumab with best supportive care (BSC) alone for advanced CRC (79).